The European Commission has cleared the planned acquisition of generic pharmaceutical company Actavis by Deutsche Bank.

Headquartered in Iceland, Actavis has a major plant in Malta and recently announced a €12m investment in a new warehouse and research facility.

The European Commission concluded that the take-over would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it.

Deutsche Bank is Actavis's most important creditor and is to acquire control over the company due to rights reserved to Deutsche Bank following a financial restructuring.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.